Loose ends worth answering
TB-500 questions that do not fit on a label
Some confusions are chemical; others come from treating a study, a story and a regulatory entry as the same kind of answer.
Is TB-500 a steroid?
No. TB-500 is the synthetic acetylated peptide fragment Ac-LKKTETQ, not a steroid hormone. It corresponds to residues 17–23 of thymosin beta-4. TB points back to that parent protein; the name supplies no study dose or clinical result.
I think this question is useful precisely because a name can carry an impression its chemistry does not support. Being a peptide does not establish safety, and being unlike a steroid does not establish a recovery benefit.
TB-500 and BPC-157: why the pairing proves so little
The two are chemically unrelated research peptides. TB-500 comes from the actin-binding region of thymosin beta-4; BPC-157 does not. The 2026 sports-medicine review discusses both among unapproved peptides, with favorable animal findings and scarce rigorous human safety data.
Their frequent appearance together in recovery discussions does not establish that a combination works, that either is safe, or that one compound can fill the other's evidentiary gaps. I see a shared reputation here; a shared clinical result remains unestablished.
How long would recovery take?
No validated human TB-500 recovery timeline appears in this record. The often-repeated wound figures come from rats given full-length thymosin beta-4: 42% greater re-epithelialization at 4 days and up to 61% at 7 days versus saline. They are not expected recovery times for people.
Likewise, more regenerating muscle fibers in mdx mice did not deliver significant strength gains. The question covers both when a biological change happens and whether it produces useful function. The research cases make that distinction concrete.
Can TB-500 be taken orally, or assigned a human half-life?
No controlled human evidence here establishes useful oral delivery of the fragment, and no validated human fragment half-life is available. The intravenous safety and pharmacokinetic study used full-length thymosin beta-4, while the detection study used horse samples.
Those studies answer their own route- and species-specific questions. They do not supply a human fragment schedule. The dosage page shows why an exact study amount can still be borrowed from the wrong experiment.
Does TB-500 cause cancer, and is long-term use safe?
Cancer causation has not been established for TB-500 in humans. Nor has long-term safety. Tumor-model work on thymosin beta-4 and human pancreatic cancer cells in culture raise a theoretical concern about cell movement and blood-vessel growth.
To me, uncertainty in both directions is the honest answer. The effects page separates that concern from anecdotal symptoms and from the missing human safety data.
Is TB-500 legal or FDA approved?
TB-500 has no FDA approval for human use. FDA records the compounding nomination as withdrawn, outside Category 2, with safety concerns retained. That does not establish Category 1 placement or new permission to compound. WADA prohibits TB-500 in and out of competition.
A licensed U.S. prescriber decides whether to prescribe; the pharmacy has separate requirements. The TB-500 legal status page gives the dated record, including the July 2026 meeting notice whose outcome is absent from the sources here.